Prevalence and severity of thrombocytopenia in patients with hyperferritinemia.

BACKGROUND In patients with tumors, inflammation, and blood disorders, hyperferritinemia has been associated with the severity of the underlying disease and is frequently accompanied by a co-occurring low platelet count or thrombocytopenia. Despite this, no established correlation has been identified between hyperferritinemia and platelet count. In this retrospective, double-center study, we sought to describe the prevalence and severity of thrombocytopenia in patients with hyperferritinemia. STUDY AND DESIGN A total of 901 samples were enrolled in this study, all of which had significantly high ferritin levels (>2000 μg/L) between January 2019 and June 2021. We analyzed the general distribution, incidence of thrombocytopenia in patients with hyperferritinemia, and the relationship between ferritin level and platelet count. p-values < 0.05 were considered statistically significant. RESULTS The total incidence of thrombocytopenia in patients with hyperferritinemia was 64.7%. Hematological diseases were the most frequent cause of hyperferritinemia (43.1%), followed by solid tumors (29.5%) and infectious diseases (11.7%). Patients with thrombocytopenia (<150 × 109/L) had significantly higher ferritin levels than those with platelet counts exceeding 150 × 109/L, with median ferritin levels of 4011 and 3221 μg/L, respectively (P < 0.001). Additionally, the results showed that the incidence of thrombocytopenia was higher in hematological patients with chronic transfusion than in those without chronic blood transfusions (93% vs 69%). CONCLUSIONS In conclusion, our results suggest that hematological diseases are the most common cause of hyperferritinemia and that patients with chronic blood transfusions are more susceptible to thrombocytopenia. Elevated ferritin levels may act as a trigger for thrombocytopenia.

[1]  F. Bauduer,et al.  Transfusional iron overload in heavily transfused patients: real-life data from a 10-year retrospective study of 611 cases managed in a French general hospital. , 2022, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[2]  Abhijit Lodha,et al.  Using first-contact serum ferritin to predict severe thrombocytopenia in dengue patients: determination and validation in independent cohorts , 2022, Infectious diseases.

[3]  Yu Wang,et al.  M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity , 2021, Signal Transduction and Targeted Therapy.

[4]  Solomon Getawa,et al.  The global prevalence of Thrombocytopenia among HIV infected adults: A systematic Review and Meta-analysis. , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[5]  M. Hou,et al.  Tumor Necrosis Factor-α Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia , 2021, Thrombosis and Haemostasis.

[6]  Fei He,et al.  Downregulation of microRNA-155-5p prevents immune thrombocytopenia by promoting macrophage M2 polarization via the SOCS1-dependent PD1/PDL1 pathway. , 2020, Life sciences.

[7]  A. Palmer,et al.  Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? , 2020, Clinica Chimica Acta.

[8]  Qi Zhou,et al.  Mechanism of thrombocytopenia in COVID-19 patients , 2020, Annals of Hematology.

[9]  S. Diamantis,et al.  Extreme hyperferritinemia: etiological spectrum and impact on prognosis. , 2020, Reumatismo.

[10]  L. Sousa,et al.  Iron overload: effects on cellular biochemistry. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[11]  I. Matsumura,et al.  Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells , 2019, Cells.

[12]  M. Michel,et al.  Iron Deficiency Anemia, a Rare and Potentially Underestimated Cause of Thrombocytopenia and a Differential Diagnosis of Immune Thrombocytopenia (ITP): Results from a Retrospective Case-Controlled Study , 2018, Blood.

[13]  J. Gong,et al.  Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl‐p53 pathway , 2018, Cancer medicine.

[14]  Sida Zhao,et al.  Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway , 2018, Cell Death & Disease.

[15]  M. Suneja,et al.  Significance of Hyperferritinemia in Hospitalized Adults☆ , 2017, The American journal of the medical sciences.

[16]  A. Killeen,et al.  Extreme Hyperferritinemia:  Causes and Impact on Diagnostic Reasoning. , 2016, American journal of clinical pathology.

[17]  M. Voso,et al.  An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms , 2015, Annals of Hematology.

[18]  J. Cheong,et al.  Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia , 2014, Transfusion.

[19]  Y. Shoenfeld,et al.  The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome , 2013, BMC Medicine.

[20]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.